Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

Rhea-AI Summary

Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. VP Investor Relations and Capital Markets Michael Levitan will join a Fireside Chat Q&A on August 12 at 10:00 EDT/16:00 CEST. Investors can arrange one-on-one meetings via Pharming’s Investor Relations team or their Canaccord Genuity representative.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46^th Annual Growth Conference in Boston on August 12-13, 2026.

Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST.

For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative.

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations and Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

• Pharming Canaccord Genuity Growth Conference_EN_04AUG2026

FAQ

When will Pharming Group (PHARM) present at the Canaccord Genuity 46th Annual Growth Conference in 2026?

Pharming Group will participate in a Fireside Chat Q&A on Wednesday, August 12, 2026 at 10:00 EDT/16:00 CEST. According to Pharming, this session is part of the Canaccord Genuity 46th Annual Growth Conference held in Boston on August 12-13, 2026.

What is Pharming Group’s role at the Canaccord Genuity 46th Annual Growth Conference 2026?

Pharming Group will take part in a Fireside Chat Q&A session at the conference. According to Pharming, VP Investor Relations and Capital Markets Michael Levitan will represent the company and speak on August 12, 2026, during the scheduled 10:00 EDT/16:00 CEST slot.

Who will represent Pharming Group (PHARM) at the 2026 Canaccord Genuity Growth Conference?

Pharming Group will be represented by Michael Levitan, VP Investor Relations and Capital Markets. According to Pharming, Levitan will participate in the Fireside Chat Q&A on August 12, 2026, and is a key contact for investors during the Boston conference.

How can investors schedule one-on-one meetings with Pharming Group (PHARM) at the 2026 Canaccord Genuity Conference?

Investors can request one-on-one meetings with Pharming’s management by contacting Pharming’s Investor Relations team or their Canaccord Genuity representative. According to Pharming, the primary contact email for investor meetings is investor@pharming.com ahead of or during the August 12-13, 2026 event.

What does Pharming Group (PHARM) do as a company participating in the 2026 Canaccord Genuity Conference?

Pharming Group is a global biopharmaceutical company focused on rare, debilitating, and life-threatening diseases. According to Pharming, it develops and commercializes innovative medicines, including small molecules and biologics, and is headquartered in Leiden, the Netherlands, with U.S. and European operations.